ProMIS Neurosciences (PMN)
NASDAQ:PMN
Want to see PMN full AI Analyst Report?
PMN Stock Chart & Stats
$8.12
-$0.04(-3.74%)
At close: 4:00 PM EST
$8.12
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$6.27 - $39.75
Previous CloseN/A
Volume32.49K
Average Volume (3M)819.50K
Market Cap
$21.85M
Enterprise Value-$49.68M
Total Cash (Recent Filing)$63.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Aug 17, 2026EPS Estimate
-1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.59
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-2.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.21
Forecast
1Y Price Target
$36.67Price Target Upside351.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-5.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Meaningful EquityThe balance sheet shows no debt and a material equity base, reducing financing cost sensitivity and bankruptcy risk. For a clinical-stage biotech, low leverage preserves optionality to raise capital on better terms, supports continued R&D spending, and extends strategic flexibility over months.
Focused Clinical-stage Antibody R&DA clear, specialized pipeline focus on antibody therapies for neurodegenerative diseases creates durable scientific differentiation. Technical barriers, regulatory pathways, and unmet clinical need in Alzheimer’s provide structural market opportunity and potential for high-value milestones if trials succeed.
Governance Continuity And Incentive FlexibilityShareholder approval of directors and a larger incentive reserve signals governance stability and gives management tools to retain key scientific talent. For a small R&D firm, equity incentives help secure specialized staff and align long‑term project execution with investor interests.
Bears Say
Pre-revenue With Large TTM Net LossThe company generates no product revenue and reported a substantial TTM net loss, indicating reliance on external financing. Persisting pre-revenue status means operational sustainability depends on successful clinical progress or capital raises, a structural vulnerability until commercialization.
Persistent Negative Free Cash Flow And Cash BurnSustained negative operating and free cash flow at material levels creates ongoing financing needs. Repeated cash burn constrains runway, forces dilution or debt financing, and can delay development timelines if new capital is slow to arrive, impacting long-term program execution.
Increased Option Reserve Raises Dilution RiskApproving a larger option and incentive reserve increases the pool available for equity grants. While useful for retention, it creates a tangible path to future dilution for existing shareholders, which is significant for a small, pre‑revenue company likely to rely on equity compensation and financing.
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $6.27 and its highest was $39.75 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $21.85M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Aug 17, 2026 which is in 75 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on May 12, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.06 by -$0.2.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -1.61.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 2,152,397 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.06. Following the earnings report the stock price went down -1.779%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ProMIS Neurosciences
ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes its proprietary technology platform to selectively target misfolded proteins implicated in these diseases, aiming to develop disease-modifying treatments. ProMIS Neurosciences operates primarily in the biotechnology and pharmaceutical sectors, leveraging advanced scientific research to address unmet medical needs in neurodegenerative conditions.
PMN Stock 12 Month Forecast
Average Price Target
$36.67
▲(351.56% Upside)